Connect with us

Biotech

C3PO vs Covid-19: MTS Tech launches disinfectant robots against the pandemic

The Catalan company MTS Tech announced the launch of a disinfection robot that would be very helpful in the hospitals’ fight to stop the spread of the coronavirus pandemic. The company expects to have fifteen robots available in medical centers until the end of the year and each one represents a cost of $67,000 (€60,000). A robot could clean a medical space in less than thirty hours.

Published

on

This picture show an hospital room.

The Spanish company MTS Tech, specialized in automation and robotic integration, has made the leap to the hospital sector with the launch of a disinfection robot valid in the fight against COVID-19. The startup hopes to reach sales of $1 million (€900,000) in 2020 with this technology. 

Find out more about the new disinfection robot the company MTS Tech wants to launch on the market in order to clean hospitals that are fighting to stop the COVID-19 pandemic and read the latest economic news in the world with our companion app Born2Invest.

How does the Robot against the pandemic work

The Catalan company has already tested its Assum system, an autonomous robot that disinfects rooms and halls using ultraviolet light, and has proven that it has the capacity to sterilize different spaces by eliminating 100% of fungi and bacteria in a very short time. The management of infrastructures and biomedical engineering of the Hospital Clínic de Barcelona and the microbiology service of the center have participated in the tests with the robot. 

The robot, equipped with ultraviolet C (UV-C) lamps, first recognizes the room to be disinfected, the algorithm calculates the distance, time and appropriate intensity based on the necessary parameters and the elements and spaces found, and the disinfection protocol is initiated once it is confirmed that no person is present. Finally, it warns that the whole process has been carried out without incident. MTS Tech already has a disinfection robot installed at the Hospital Clínic in Barcelona. The cost of each disinfection robot is $67,000 (€60,000), as Maria Visa, CEO of MTS Tech said.

SEE ALSO  Is cannabis legal in Italy? The answer is complicated

MTS Tech already has a disinfection robot installed in the Hospital Clínic de Barcelona

The company’s objective is to put in place fifteen robots in hospitals or medical centers from now until the end of the year, so the sales of the equipment would bring in close to $1.13 million (€1 million). To date, the company has worked for industries such as the chemical, food, and intralogistics sectors, on projects related to heat-cooling, ultrasound, and consultancy. 

The startup was founded in 2019 and the two partners are Visa and Toni Jurado, engineer by the Escola Universitària Politècnica de Mataró and expert in intralogistics.

Although so far the company has financed itself from its own resources and has allocated the profits obtained to investment in new technology, it does not rule out opening a round of financing in 2021 to cover new markets. However, Visa makes it clear that there is nothing firm at present.  

MTS Tech’s robot can disinfect a hospital room in less than thirty hours 

With traditional systems based on cleaning cycles, the closing of units and the natural decay of pathogens, a complete hospital disinfection process can take more than 48-72 hours. 

Visa said that, with its technology, a medical space can be clean in less than thirty hours. “With this protocol we can drastically reduce the time needed to carry out the correct bio-decontamination of the spaces, while guaranteeing maximum security for the professionals,” explained Visa. In addition, studies will begin to analyze whether the robot is also effective in disinfecting areas where there has been Sars-CoV-2.

SEE ALSO  Choosing between impact investing charitable donations

__

(Featured image by corgaasbeek via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anne Kings is a reporter for the financial sector, often tackling Wall Street and shareholders' interests. She also covers the intersection of media and technology, and delves into interesting topics on entertainment. Sometimes she also writes about the cannabis industry, in particular CBD and hemp. She is currently based in New York.